Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief Business Officer [Yahoo! Finance]
Pieris Pharmaceuticals, Inc. (PIRS)
NASDAQ:AMEX Investor Relations:
ir.pieris.com
Company Research
Source: Yahoo! Finance
cancer immunotherapies, announces the appointment of Eckhard Niemeier as its Chief Business Officer (CBO). With over 20 years of experience in life sciences corporate development and strategy, Eckhard will work closely with the leadership team and play a key role in shaping Nouscom's growth. Dr. Marina Udier, CEO of Nouscom , commented on the appointment: “ We are delighted to welcome Eckhard to Nouscom. His proven track record in forging collaborations with leading pharmaceutical and biotech companies aligns perfectly with our vision for growth and innovation. The next 12 months will be an exciting time for Nouscom as we anticipate key data readouts from clinical trials with our lead asset, NOUS-209, in dMMR/MSI metastatic CRC and in Lynch Syndrome carriers. I look forward to working with Eckhard and the leadership team to shape the next phase of growth for the company, leveraging both our pipeline opportunities, such as NOUS-PEV, and the broad potential of our innovative platform
Show less
Read more
Impact Snapshot
Event Time:
PIRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PIRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PIRS alerts
High impacting Pieris Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PIRS
News
- PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRSBusiness Wire
- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic MalformationsGlobeNewswire
PIRS
Sec Filings
- 12/20/24 - Form SCHEDULE
- 12/20/24 - Form SCHEDULE
- 12/20/24 - Form SCHEDULE
- PIRS's page on the SEC website